Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Beam Therapeutics Inc. or Fortrea Holdings Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Beam Therapeutics Inc. and Fortrea Holdings Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Beam Therapeutics Inc. and Fortrea Holdings Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Latest Biotechnology and Beam Therapeutics Inc., Fortrea Holdings Inc. Stock News

As of July 31, 2026, Beam Therapeutics Inc. had a $2.5 billion market capitalization, compared to the Biotechnology median of $252.6 million. Beam Therapeutics Inc.’s stock is down 7.9% in 2026, up 1.7% in the previous five trading days and up 26.65% in the past year.

Currently, Beam Therapeutics Inc. does not have a price-earnings ratio. Beam Therapeutics Inc.’s trailing 12-month revenue is $164.0 million with a -40.2% net profit margin. Year-over-year quarterly sales growth most recently was 322.7%. Analysts expect adjusted earnings to reach $-4.435 per share for the current fiscal year. Beam Therapeutics Inc. does not currently pay a dividend.

As of July 31, 2026, Fortrea Holdings Inc. had a $1.8 billion market cap, putting it in the 53rd percentile of all stocks. Fortrea Holdings Inc.’s stock is up 11.1% in 2026, down 1.8% in the previous five trading days and up 209.19% in the past year.

Currently, Fortrea Holdings Inc. does not have a price-earnings ratio. Fortrea Holdings Inc.’s trailing 12-month revenue is $2.7 billion with a -3.2% net profit margin. Year-over-year quarterly sales growth most recently was -4.5%. Analysts expect adjusted earnings to reach $0.845 per share for the current fiscal year. Fortrea Holdings Inc. does not currently pay a dividend.

How We Compare Beam Therapeutics Inc. and Fortrea Holdings Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Beam Therapeutics Inc. and Fortrea Holdings Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Beam Therapeutics Inc. and Fortrea Holdings Inc. Growth Grades

Company	Ticker	Growth
Beam Therapeutics Inc.	BEAM	na
Fortrea Holdings Inc.	FTRE	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Beam Therapeutics Inc. does not have a meaningful Growth Score. Fortrea Holdings Inc. has a Growth Score of 56, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Beam Therapeutics Inc. or Fortrea Holdings Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Beam Therapeutics Inc. or Fortrea Holdings Inc. is the better investment when it comes to sustainable growth.

Beam Therapeutics Inc. and Fortrea Holdings Inc.’s Quality Grades

Company	Ticker	Quality
Beam Therapeutics Inc.	BEAM	D
Fortrea Holdings Inc.	FTRE	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Beam Therapeutics Inc. has a Quality Score of 22, which is Weak. Fortrea Holdings Inc. has a Quality Score of 57, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Beam Therapeutics Inc. or Fortrea Holdings Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Beam Therapeutics Inc. or Fortrea Holdings Inc. is the better investment when it comes to quality.

Beam Therapeutics Inc. and Fortrea Holdings Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Beam Therapeutics Inc.	BEAM	C
Fortrea Holdings Inc.	FTRE	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Beam Therapeutics Inc. has a Earnings Estimate Score of 59, which is Neutral. Fortrea Holdings Inc. has a Earnings Estimate Score of 78, which is Positive.

The Earnings Estimate Revisions Grade Winner: Fortrea Holdings Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Fortrea Holdings Inc. has a better Earnings Estimate Revisions Grade than Beam Therapeutics Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Fortrea Holdings Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Beam Therapeutics Inc. and Fortrea Holdings Inc. Grades

In addition to Growth, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Beam Therapeutics Inc. and Fortrea Holdings Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Beam Therapeutics Inc. or Fortrea Holdings Inc. Stock?

Overall, Beam Therapeutics Inc. stock has a Growth Score of , Estimate Revisions Score of 59 and Quality Score of 22.

Fortrea Holdings Inc. stock has a Growth Score of 56, Estimate Revisions Score of 78 and Quality Score of 57.

Comparing Beam Therapeutics Inc. and Fortrea Holdings Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.